Hydrocodone/paracetamol - Mallinckrodt

Drug Profile

Hydrocodone/paracetamol - Mallinckrodt

Alternative Names: hydrocodone/acetaminophen - Mallinckrodt; QSC-001

Latest Information Update: 10 Apr 2015

Price : $50

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Adare Pharmaceuticals
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 14 Aug 2014 Questcor Pharmaceuticals has been acquired by Mallinckrodt plc
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top